Response to rebuttal: Sikiric defense of BPC-157 safety profile
Sikiric/PMC/2025
Why It Matters
Sikiric (the principal BPC-157 researcher) responds to Jozwiak et al. rebuttal. Defends the safety profile and anti-tumor evidence for BPC-157.
Key Findings
- Defends BPC-157 safety profile across 100+ published studies
- Notes no observed toxicity at any tested dose in animal models
Read the Paper↗PMC12567428